Cargando…
A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916300/ https://www.ncbi.nlm.nih.gov/pubmed/27176798 http://dx.doi.org/10.1038/bcj.2016.31 |
| _version_ | 1782438807486857216 |
|---|---|
| author | Becker, P S Gooley, T A Green, D J Burwick, N Kim, T Y Kojouri, K Inoue, Y Moore, D J Nelli, E Dennie, T Bensinger, W I |
| author_facet | Becker, P S Gooley, T A Green, D J Burwick, N Kim, T Y Kojouri, K Inoue, Y Moore, D J Nelli, E Dennie, T Bensinger, W I |
| author_sort | Becker, P S |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4916300 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-49163002016-06-30 A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma Becker, P S Gooley, T A Green, D J Burwick, N Kim, T Y Kojouri, K Inoue, Y Moore, D J Nelli, E Dennie, T Bensinger, W I Blood Cancer J Letter to the Editor Nature Publishing Group 2016-05 2016-05-13 /pmc/articles/PMC4916300/ /pubmed/27176798 http://dx.doi.org/10.1038/bcj.2016.31 Text en Copyright © 2016 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Becker, P S Gooley, T A Green, D J Burwick, N Kim, T Y Kojouri, K Inoue, Y Moore, D J Nelli, E Dennie, T Bensinger, W I A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma |
| title | A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma |
| title_full | A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma |
| title_fullStr | A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma |
| title_full_unstemmed | A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma |
| title_short | A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma |
| title_sort | phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916300/ https://www.ncbi.nlm.nih.gov/pubmed/27176798 http://dx.doi.org/10.1038/bcj.2016.31 |
| work_keys_str_mv | AT beckerps aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT gooleyta aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT greendj aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT burwickn aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT kimty aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT kojourik aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT inouey aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT mooredj aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT nellie aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT denniet aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT bensingerwi aphase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT beckerps phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT gooleyta phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT greendj phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT burwickn phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT kimty phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT kojourik phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT inouey phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT mooredj phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT nellie phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT denniet phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma AT bensingerwi phase2studyofbortezomibcyclophosphamidepegylatedliposomaldoxorubicinanddexamethasonefornewlydiagnosedmultiplemyeloma |